
Gland Pharma Ltd. Gland Pharma
Gland Pharma
Gland Pharma Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
| Ex-Date | Purpose |
|---|---|
21-07-2021 | Quarterly Results |
22-10-2021 | Quarterly Results |
21-01-2022 | Quarterly Results |
19-05-2022 | Audited Results |
20-07-2022 | Quarterly Results |
26-10-2022 | Quarterly Results |
23-01-2023 | Quarterly Results |
18-05-2023 | Audited Results |
18-05-2023 | A.G.M. |
07-08-2023 | Quarterly Results |
07-08-2023 |
|
06-11-2023 | Quarterly Results |
14-02-2024 | Quarterly Results |
04-11-2024 | Quarterly Results |
03-02-2025 | Quarterly Results |
20-05-2025 | Audited Results & Final Dividend |
05-08-2025 | Quarterly Results |
03-11-2025 | Quarterly Results |
28-01-2026 | Quarterly Results |
15-05-2026 | Final Dividend & Audited Results |
10-08-2026 | Quarterly Results |
06-11-2026 | Quarterly Results |
News
Gland Pharma informs about appointment of chief investment officer
Gland Pharma zooms as its consolidated net profit grows 58% in Q2
The total consolidated income of the company has increased by 21.11% at Rs 1,902.64 crore for Q2FY27
Gland Pharma’s consolidated net profit grows 58% in Q2
The total consolidated income of the company has increased by 21.11% at Rs 1,902.64 crore for Q2FY27
Gland Pharma reports Profit after tax of Rs 4248.76 Mln, in the September 2026 quarter
Gland Pharma informs about press release
Gland Pharma gets USFDA’s approval for Methylprednisolone Acetate Injectable Suspension
According to IQVIA, the Methylprednisolone injection had US sales of approximately $214 million for the twelve months ending August 2026
USFDA concludes unannounced inspection at Gland Pharma’s Dundigal formulation facility
The said inspection was concluded with four Form 483 Observations
Gland Pharma informs about disclosure
Gland Pharma informs about newspaper publication
USFDA completes routine GMP inspection at Gland Pharma’s Visakhapatnam facility
The inspection was concluded with ZERO Form 483 Observations
Gland Pharma informs about appointment of chief executive officer
Gland Pharma zooms on reporting 47% jump in Q1 consolidated net profit
The total consolidated income of the company has increased by 19.09% at Rs 1,861.50 crore for Q1FY27
Gland Pharma reports 47% jump in Q1 consolidated net profit
The total consolidated income of the company has increased by 19.09% at Rs 1,861.50 crore for Q1FY27
Gland Pharma - Quaterly Results
Gland Pharma reports Profit after tax of Rs 3643.91 Mln, in the June 2026 quarter
Gland Pharma soars on executing strategic agreement with Global Pharmaceutical Company
The agreement is for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for global markets
Gland Pharma executes strategic agreement with Global Pharmaceutical Company
The agreement is for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for global markets
Gland Pharma gains on partnering with Neuland Laboratories
The company will establish a sterile manufacturing suite for APIs pertaining to microparticle depot products
Gland Pharma, Neuland Laboratories join forces for sterile API manufacturing
The company will establish a sterile manufacturing suite for APIs pertaining to microparticle depot products
Gland Pharma trades higher on getting USFDA’s approval for Sugammadex Injection
According to IQVIA, the product had US sales of approximately $1.6 billion for the twelve months ending April 2026
Gland Pharma gets USFDA’s approval for Sugammadex Injection
According to IQVIA, the product had US sales of approximately $1.6 billion for the twelve months ending April 2026
Gland Pharma informs about press release
Gland Pharma informs about board meeting
Gland Pharma informs about allotment of equity shares
Gland Pharma shines on reporting jumps 97% in Q4 consolidated net profit
The total consolidated income of the company increased by 26.23% at Rs 1,854.26 crore for Q4FY26
Gland Pharma’s consolidated net profit jumps 97% in Q4
The total consolidated income of the company increased by 26.23% at Rs 1,854.26 crore for Q4FY26
Gland Pharma informs about newspaper advertisement
Gland Pharma - Quaterly Results
Gland Pharma reports Profit after tax of Rs 4204.51 Mln, in the March 2026 quarter
Gland Pharma informs about press release
Gland Pharma gets USFDA’s tentative nod for Brimonidine Tartrate Ophthalmic Solution
The product is indicated to relieve redness of the eye
Gland Pharma informs about change in management
Gland Pharma informs about analyst meet
Gland Pharma gets USFDA’s approval for Zoledronic Acid Injection
This Product is indicated to treat Hypercalcemia of Malignancy and Multiple Myeloma and Bone Metastases of Solid Tumors
Gland Pharma - Quaterly Results
Gland Pharma reports Profit after tax of Rs 3078.47 Mln, in the December 2025 quarter
Gland Pharma rises on getting nod for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
This product is indicated for the treatment of ocular itching associated with allergic conjunctivitis
Gland Pharma gets nod for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
This product is indicated for the treatment of ocular itching associated with allergic conjunctivitis
Gland Pharma reports 12% rise in Q2 consolidated net profit
The consolidated total income of the company increased by 7.20% at Rs 1,571.04 crore for Q2FY26
Gland Pharma - Quaterly Results
Gland Pharma informs about outcome of board meeting
Gland Pharma reports Profit after tax of Rs 3019.95 Mln, in the September 2025 quarter
Gland Pharma informs about earnings call
Gland Pharma informs about analyst meet
Gland Pharma informs about investor meetings
Gland Pharma receives USFDA’s approval for Vasopressin in 5% Dextrose RTU Injection
According to IQVIA, the product had US sales of approximately $45 million for the twelve months ending June 2025
Gland Pharma gets USFDA’s nod for Cangrelor for Injection
The product had US sales of around $122 million for the twelve months ending June 2025
Gland Pharma gets USFDA’s approval for Norepinephrine Bitartrate
The company is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity
Gland Pharma informs about press release
Gland Pharma informs about press release
Gland Pharma shines on reporting 50% jump in Q1 consolidated net profit
The total consolidated income of the company increased by 7.57% at Rs 1563.15 crore for Q1FY26
Gland Pharma reports 50% jump in Q1 consolidated net profit
The total consolidated income of the company increased by 7.57% at Rs 1563.15 crore for Q1FY26
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma reports Profit after tax of Rs 2692.58 Mln, in the June 2025 quarter
Gland Pharma informs about BRSR
Gland Pharma gains on getting GMP Compliance Certificate for Pashamylaram facility
The company has received certificate of GMP for aseptically prepared Powder for injection, infusion and inhalation
Gland Pharma gets GMP Compliance Certificate for Pashamylaram facility
The company has received certificate of GMP for aseptically prepared Powder for injection, infusion and inhalation
Gland Pharma soars on getting EIR from USFDA for Visakhapatnam facility
The said inspection was conducted between February 19, 2025 and February 25, 2025
Gland Pharma gets EIR from USFDA for Visakhapatnam facility
The said inspection was conducted between February 19, 2025 and February 25, 2025
Gland Pharma’s subsidiary gets 11 observations for Fontenay manufacturing facility
There will be no disruption in the manufacturing operations due to this final inspection report
Gland Pharma informs about press release
Gland Pharma submits press release
Gland Pharma inches up on getting USFDA’s approval for Angiotensin II Acetate Injection
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), GIAPREZA of La Jolla Pharma LLC
Gland Pharma gets USFDA’s approval for Angiotensin II Acetate Injection
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), GIAPREZA of La Jolla Pharma LLC
Gland Pharma informs about annual secretarial compliance report
Gland Pharma reports Profit after tax of Rs 2899.99 Mln, in the March 2025 quarter
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma informs about board meeting
Gland Pharma rises on getting USFDA’s nod for Latanoprostene Bunod Ophthalmic Solution
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Gland Pharma gets USFDA’s nod for Latanoprostene Bunod Ophthalmic Solution
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Gland Pharma informs about change in contact details of RTA
Gland Pharma informs about disclosure
Gland Pharma informs about confirmation certificate
Pharma stocks trade lower amid fears of Trump’s tariff on pharma imports
Gland Pharma is currently trading at Rs. 1383.00, down by 42.55 points or 2.98%
Gland Pharma informs about press release
Gland Pharma surges on receiving USFDA’s approval for Acetaminophen Injection
This product is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
Gland Pharma receives USFDA’s approval for Acetaminophen Injection
This product is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
Gland Pharma jumps as USFDA concludes pre-approval inspection at Visakhapatnam facility
The said inspection was concluded with three form 483 observations
USFDA concludes pre-approval inspection at Visakhapatnam facility of Gland Pharma
The said inspection was concluded with three form 483 observations
Gland Pharma reports 7% rise in Q3 consolidated net profit
Total consolidated income of the company decreased by 8.85% at Rs 1442.55 crore for Q3FY25
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma reports Profit after tax of Rs 2951.23 Mln, in the December 2024 quarter
Gland Pharma gets EIR from USFDA for Pashamylaram facility
USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 25, 2024 and August 02, 2024
Gland Pharma submits board meeting intimation
Gland Pharma gets EIR from USFDA for Hyderabad facility
USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 22, 2024 and July 25, 2024
Gland Pharma shines on getting USFDA’s approval for Phytonadione Injectable Emulsion
The Product is bioequivalent and therapeutically equivalent to the RLD, Vitamin K1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc.
Gland Pharma gets USFDA’s approval for Phytonadione Injectable Emulsion
The Product is bioequivalent and therapeutically equivalent to the RLD, Vitamin K1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc.
Gland Pharma informs about analyst meet
Gland Pharma jumps on getting USFDA’s nod for Latanoprost Ophthalmic Solution
This Product is used for the treatment of high eye pressure/intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Gland Pharma gets USFDA’s nod for Latanoprost Ophthalmic Solution
This Product is used for the treatment of high eye pressure/intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Gland Pharma informs about press release
Gland Pharma informs about analyst meet
Gland Pharma zooms despite reporting 16% fall in Q2 consolidated net profit
Consolidated total income of the company increased by 2.73% at Rs 1,465.49 crore for Q2FY25
Gland Pharma reports 16% fall in Q2 consolidated net profit
Consolidated total income of the company increased by 2.73% at Rs 1,465.49 crore for Q2FY25
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma reports Profit after tax of Rs 2817.10 Mln, in the September 2024 quarter
Gland Pharma shines on getting USFDA’s approval for Eribulin Mesylate Injection
The company expects to launch this product in the near term through its marketing partner
Gland Pharma gets USFDA’s approval for Eribulin Mesylate Injection
The company expects to launch this product in the near term through its marketing partner
Gland Pharma informs about earnings call transcript
Gland Pharma - Quaterly Results
Gland Pharma reports Profit after tax of Rs 2768.05 Mln, in the December 2023 quarter
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma informs about analyst meet
Gland Pharma informs about analyst meet
Gland Pharma informs about disclosure
Gland Pharma surges on getting EIR for Pashamylaram Facility
The Pre-Market Inspection was conducted between August 23, 2023 and August 26, 2023
Gland Pharma gets EIR for Pashamylaram Facility
The Pre-Market Inspection was conducted between August 23, 2023 and August 26, 2023
Gland Pharma informs about analyst meet
Gland Pharma moves up on getting USFDA’s tentative nod for Angiotensin II Injection
The company will launch the product with its marketing partner on receipt of final approval
Gland Pharma informs about press release
Gland Pharma gets USFDA’s tentative nod for Angiotensin II Injection
The company will launch the product with its marketing partner on receipt of final approval
Gland Pharma informs about receipt of establishment inspection report from US FDA
Gland Pharma gets EIR for VSEZ Sterile Oncology Facility
The GMP Inspection was conducted by USFDA between July 20, 2023 and July 28, 2023
Gland Pharma informs about press release
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma reports Profit after tax of Rs 2575.27 Mln, in the September 2023 quarter
Gland Pharma informs about disclosure
Gland Pharma informs about disclosure
Gland Pharma informs about conclusion of US FDA inspection at pashamylaram facility
USFDA concludes inspection at Gland Pharma’s Pashamylaram Facility
The company has received Establishment Inspection Report
Gland Pharma informs about analyst meet
Gland Pharma informs about analyst meet
USFDA conducts inspection at Gland Pharma’s Pashamylaram Facility in Hyderabad
The company has received 2 observations on Form 483 with respect to ANDA filed for the product to be manufactured in a PEN device
Gland Pharma trades higher on the BSE
The company has received EIR for Dundigal facility
Gland Pharma gets EIR for Dundigal facility
USFDA had conducted inspection at the said manufacturing facility from July 03, 2023 to July 14, 2023
Gland Pharma reports Profit after tax of Rs 1875.82 Mln, in the June 2023 quarter
Gland Pharma - Quaterly Results
USFDA concludes GMP inspection at Gland Pharma’s Visakhapatnam facility
The inspection was concluded with (Zero) 483 observations and a classification of No Action Indicated
USFDA concludes GMP inspection at Gland Pharma’s Dundigal facility
The inspection was concluded with (1) 483 Observation
Gland Pharma informs about disclosure
USFDA concludes PAI, GMP inspection at Gland Pharma’s Pashamylaram facility
The inspection was concluded with (1) 483 observation
Gland Pharma informs about analyst meet
Gland Pharma reports 72% fall in Q4 consolidated net profit
Total consolidated income of the company decreased by 29.47% at Rs 823.95 crore for Q4FY23
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma reports Profit after tax of Rs 792.06 Mln, in the March 2023 quarter
Gland Pharma informs about analyst meet
Gland Pharma informs about analyst meet
Gland Pharma submits analyst meet intimation
Gland Pharma informs about updates
Gland Pharma informs about analyst meet
Gland Pharma trades higher on the bourses
The company is planning to invest Rs 400 crore to expand Telangana’s existing facility
Gland Pharma jumps on planning to invest Rs 400 crore to expand Telangana’s existing facility
The expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places
Gland Pharma planning to invest Rs 400 crore to expand Telangana’s existing facility
The expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places
Gland Pharma informs about analyst meet
USFDA conducts inspection at Gland Pharma’s API Facility in Visakhapatnam
The inspection has been completed with Zero observations
Gland Pharma informs about analyst meet
Gland Pharma shines despite reporting 15% fall in Q3 consolidated net profit
Total income of the company decreased by 9.85% to Rs 999.80 crore for Q3FY23
Gland Pharma reports 15% fall in Q3 consolidated net profit
Total consolidated income of the company decreased by 9.85% to Rs 999.80 crore for Q3FY23
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma - Quaterly Results
Gland Pharma trades higher on the BSE
The company has receivied EIR from US FDA for Dundigal Facility at Hyderabad
Gland Pharma receives EIR from US FDA for Dundigal Facility at Hyderabad
Earlier, the Pre-Market Inspection covering US FDA’s Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) was conducted between August 22-25, 2022
Gland Pharma informs about trading window closure
Gland Pharma informs about investors meeting
Gland Pharma informs about analyst meet intimation
Gland Pharma informs about analyst meet
Gland Pharma enters into put option agreement to acquire 100% stake in Cenexi Group
The acquisition provides Gland Pharma access to leading know-how and development capabilities in sterile forms including for ophthalmic gel, needleless injectors and hormones
Gland Pharma informs about analyst meet intimation
Gland Pharma informs about investors meet
Gland Pharma reports 20% fall in Q2 consolidated net profit
Total consolidated income of the company decreased by 1.91% at Rs 1110.03 crore for Q2FY23